<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    17968921
   </pmid>
   <datecreated>
    <year>
     2007
    </year>
    <month>
     11
    </month>
    <day>
     26
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2007
    </year>
    <month>
     12
    </month>
    <day>
     19
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2008
    </year>
    <month>
     10
    </month>
    <day>
     23
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0004-3591
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       56
      </volume>
      <issue>
       11
      </issue>
      <pubdate>
       <year>
        2007
       </year>
       <month>
        Nov
       </month>
      </pubdate>
     </journalissue>
     <title>
      Arthritis and rheumatism
     </title>
     <isoabbreviation>
      Arthritis Rheum.
     </isoabbreviation>
    </journal>
    <articletitle>
     Efficacy and safety of intraarticular hylan or hyaluronic acids for osteoarthritis of the knee: a randomized controlled trial.
    </articletitle>
    <pagination>
     <medlinepgn>
      3610-9
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To compare the efficacy and safety of intraarticular hylan and 2 hyaluronic acids (HAs) in osteoarthritis (OA) of the knee.
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      This was a multicenter, patient-blind, randomized controlled trial in 660 patients with symptomatic knee OA. Patients were randomly assigned to receive 1 cycle of 3 intraarticular injections per knee of 1 of 3 preparations: a high molecular weight cross-linked hylan, a non-cross-linked medium molecular weight HA of avian origin, or a non-cross-linked low molecular weight HA of bacterial origin. The primary outcome measure was the change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score at 6 months. Secondary outcome measures included local adverse events (effusions or flares) in injected knees. During months 7-12, patients were offered a second cycle of viscosupplementation.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      Pain relief was similar in all 3 groups. The difference in changes between baseline and 6 months between hylan and the combined HAs was 0.1 on the WOMAC pain score (95% confidence interval [95% CI] -0.2, 0.3). No relevant differences were observed in any of the secondary efficacy outcomes, and stratified analyses provided no evidence for differences in effects across different patient groups. There was a trend toward more local adverse events in the hylan group than in the HA groups during the first cycle (difference 2.2% [95% CI -2.4, 6.7]), and this trend became more pronounced during the second cycle (difference 6.4% [95% CI 0.6, 12.2]).
     </abstracttext>
     <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
      We found no evidence for a difference in efficacy between hylan and HAs. In view of its higher costs and potential for more local adverse events, we see no rationale for the continued use of hylan in patients with knee OA.
     </abstracttext>
    </abstract>
    <affiliation>
     University of Berne, Berne, Switzerland. juni@ispm.unibe.ch
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Jüni
      </lastname>
      <forename>
       Peter
      </forename>
      <initials>
       P
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Reichenbach
      </lastname>
      <forename>
       Stephan
      </forename>
      <initials>
       S
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Trelle
      </lastname>
      <forename>
       Sven
      </forename>
      <initials>
       S
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Tschannen
      </lastname>
      <forename>
       Beatrice
      </forename>
      <initials>
       B
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Wandel
      </lastname>
      <forename>
       Simon
      </forename>
      <initials>
       S
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Jordi
      </lastname>
      <forename>
       Beat
      </forename>
      <initials>
       B
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Züllig
      </lastname>
      <forename>
       Maya
      </forename>
      <initials>
       M
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Guetg
      </lastname>
      <forename>
       Reto
      </forename>
      <initials>
       R
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Häuselmann
      </lastname>
      <forename>
       Hans Jörg
      </forename>
      <initials>
       HJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Schwarz
      </lastname>
      <forename>
       Hans
      </forename>
      <initials>
       H
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Theiler
      </lastname>
      <forename>
       Robert
      </forename>
      <initials>
       R
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Ziswiler
      </lastname>
      <forename>
       Hans Rudolf
      </forename>
      <initials>
       HR
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Dieppe
      </lastname>
      <forename>
       Paul A
      </forename>
      <initials>
       PA
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Villiger
      </lastname>
      <forename>
       Peter M
      </forename>
      <initials>
       PM
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Egger
      </lastname>
      <forename>
       Matthias
      </forename>
      <initials>
       M
      </initials>
     </author>
     <author validyn="Y">
      <collectivename>
       Swiss Viscosupplementation Trial Group
      </collectivename>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <databanklist completeyn="Y">
     <databank>
      <databankname>
       ISRCTN
      </databankname>
      <accessionnumberlist>
       <accessionnumber>
        ISRCTN51421587
       </accessionnumber>
      </accessionnumberlist>
     </databank>
    </databanklist>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Multicenter Study
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     Arthritis Rheum
    </medlineta>
    <nlmuniqueid>
     0370605
    </nlmuniqueid>
    <issnlinking>
     0004-3591
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Adjuvants, Immunologic
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Biocompatible Materials
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      125935-84-4
     </registrynumber>
     <nameofsubstance>
      hylan
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      9004-61-9
     </registrynumber>
     <nameofsubstance>
      Hyaluronic Acid
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="CommentIn">
     <refsource>
      ACP J Club. 2008 Mar-Apr;148(2):42
     </refsource>
     <pmid version="1">
      18311872
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Nat Clin Pract Rheumatol. 2008 Aug;4(8):400-1
     </refsource>
     <pmid version="1">
      18594492
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Arthritis Rheum. 2008 May;58(5):1560-1; author reply 1561-2
     </refsource>
     <pmid version="1">
      18438827
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adjuvants, Immunologic
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Biocompatible Materials
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hyaluronic Acid
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      analogs &amp; derivatives
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Injections, Intra-Articular
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Osteoarthritis, Knee
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pain
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Quality of Life
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Treatment Outcome
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2007
     </year>
     <month>
      10
     </month>
     <day>
      31
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2007
     </year>
     <month>
      12
     </month>
     <day>
      20
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2007
     </year>
     <month>
      10
     </month>
     <day>
      31
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="doi">
     10.1002/art.23026
    </articleid>
    <articleid idtype="pubmed">
     17968921
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

